Wolfgang Schmitt
YOU?
Author Swipe
View article: Spatial proteomics of ovarian cancer precursors delineates early disease changes and drug targets
Spatial proteomics of ovarian cancer precursors delineates early disease changes and drug targets Open
High-grade serous ovarian cancer (HGSOC) is often detected at an advanced stage, where curative treatment options are limited. Recent advances in ultrasensitive mass spectrometry-based spatial proteomics have provided a unique opportunity …
View article: Figure S10 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Figure S10 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Figure S10 displays differences in celltypes between the cohorts A) for LTS and B) for STS based on CIBERSORT results.
View article: Table S1 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Table S1 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
The Table S1 shows the Patient ID, Cancer Stage and the Residual _Tumor status of the TCGA paired cohort grouped by the Survival Group.
View article: Table S4 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Table S4 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Table S4 displays the characteristics and subtypes of the Charité cohort.
View article: Table S5 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Table S5 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Table S5 depicts the BRCA1/2, KRAS Status and HRD-Scores in LTS and STS in the Charité Cohort.
View article: Figure S1 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Figure S1 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Figure S1 shows a REMARK Diagram of the Charité Cohort construction.
View article: Figure S2 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Figure S2 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Figure S2 displays the Proportions of Molecular subtypes of LTS and STS in the Charité cohort and n the TCGA cohort.
View article: Data from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Data from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Purpose:The late-stage diagnosis and the aggressiveness of high-grade serous tubo-ovarian carcinoma (HGSC) often result in poor survival outcomes, yet some patients exhibit an exceptionally long survival rate. This study aimed to identify …
View article: Figure S5 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Figure S5 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Figure S5 shows Candidate Genes in the Charité Cohort and Correlations among candidate genes and Literature research results for candidate genes.
View article: Figure S7 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Figure S7 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Figure S7 shows the Mutation Landscape of TCGA LTS and STS Patients.
View article: Figure S6 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Figure S6 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Figure S6 presents Boxplots showing differences in BRCA1/2, KRAS, RB1, CCNE1 expression between LTS and STS in the Charité cohort.
View article: Table S3 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Table S3 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Table S3 shows the likelihoods estimated by ConsensusOV for the subtypes of Charité STS and LTS.
View article: Table S2 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Table S2 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Table S2 shows the settings for digital image analysis in QuPath for the three IHC markers (CD3,CD4, CD8)
View article: Figure S8 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Figure S8 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Figure S8 depicts GSEA for Millstein sub-signatures in the Charité cohort. Gene sets were incrementally increased by one gene at thetime (see color code). X-axis shows the NES and only the full 101-gene signature was significantly enriched.
View article: Figure S3 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Figure S3 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Figure S3 shows the Gene count Distribution before and after quality filtering in the Charité Cohort and in the TCGA subcohort.
View article: Figure S9 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Figure S9 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Figure S9 shows CIBERSORT estimated celltypes per sample in the Charité cohort and in the TCGA cohort.
View article: Figure S4 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer
Figure S4 from Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-grade Serous Tubo-ovarian Cancer Open
Figure S4 shows the results of the DEG Analysis in the TCGA cohort A. DEGs in the TCGA (red = up in STS, blue = up in LTS) cohort B. Volcano plot
View article: Supplementary Material 1 from GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer—A Study of the GANNET53 Consortium
Supplementary Material 1 from GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer—A Study of the GANNET53 Consortium Open
Supplementary Figures and Tables
View article: Data from GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer—A Study of the GANNET53 Consortium
Data from GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer—A Study of the GANNET53 Consortium Open
Purpose:Mutant p53 stabilized by heat shock protein 90 (HSP90) is a novel target in oncology. The open-label, randomized phase II GANNET53 trial is the first to evaluate the HSP90 inhibitor ganetespib (G) with paclitaxel (P) in platinum-re…
View article: Implementation and outcome of personalized treatment strategies in advanced genitourinary cancers
Implementation and outcome of personalized treatment strategies in advanced genitourinary cancers Open
For a majority of GU cancer patients an MMT was identified and responses were seen in heavily pretreated patients. Additional controlled trials and integration of comprehensive molecular analyses and subsequent personalized therapy should …
View article: GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer—A Study of the GANNET53 Consortium
GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer—A Study of the GANNET53 Consortium Open
Purpose: Mutant p53 stabilized by heat shock protein 90 (HSP90) is a novel target in oncology. The open-label, randomized phase II GANNET53 trial is the first to evaluate the HSP90 inhibitor ganetespib (G) with paclitaxel (P) in platinum-r…
View article: Supplementary Figure S2 from Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD—Long-term Survival of the GeparOLA Study
Supplementary Figure S2 from Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD—Long-term Survival of the GeparOLA Study Open
Figure S2: 4-year loco-regional recurrence rate according to treatment arm (PO vs PCb)
View article: Supplementary Table S2 from Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD—Long-term Survival of the GeparOLA Study
Supplementary Table S2 from Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD—Long-term Survival of the GeparOLA Study Open
Table S2: Secondary endpoints by treatment arm and pCR
View article: Data from Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD—Long-term Survival of the GeparOLA Study
Data from Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD—Long-term Survival of the GeparOLA Study Open
Purpose:The GeparOLA study evaluated paclitaxel plus olaparib (PO) in neoadjuvant chemotherapy for patients with HER2-negative early breast cancer with homologous recombination deficiency (HRD). HRD was defined by high HRD score or germlin…
View article: Supplementary Figure S1 from Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD—Long-term Survival of the GeparOLA Study
Supplementary Figure S1 from Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD—Long-term Survival of the GeparOLA Study Open
Figure S1: Representativeness of Study Participants (Consort diagram)
View article: Supplementary Table S1 from Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD—Long-term Survival of the GeparOLA Study
Supplementary Table S1 from Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD—Long-term Survival of the GeparOLA Study Open
Table S1: First iDFS event
View article: Supplementary Table S3 from Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD—Long-term Survival of the GeparOLA Study
Supplementary Table S3 from Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD—Long-term Survival of the GeparOLA Study Open
Representativeness of Study Participants
View article: Supplementary Figure S3 from Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD—Long-term Survival of the GeparOLA Study
Supplementary Figure S3 from Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD—Long-term Survival of the GeparOLA Study Open
Figure S3: Screening for Patients: HRD Status and g/tBRCA1/2 Mutations
View article: Deep spatial proteomics of ovarian cancer precursor lesions delineates early disease changes and cell-of-origin signatures
Deep spatial proteomics of ovarian cancer precursor lesions delineates early disease changes and cell-of-origin signatures Open
Summary High-grade serous ovarian cancer (HGSOC) is a devastating disease that is frequently detected at an incurable stage. Advances in ultrasensitive mass spectrometry-based spatial proteomics have provided a unique opportunity to uncove…